Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Mycotopia Therapies Inc TPIA

Mycotopia Therapies Inc provides psychedelic therapies through technology-focused, data-driven, and medical-based solutions for people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions.


Recent & Breaking News (OTCPK:TPIA)

Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ

GlobeNewswire May 23, 2022

Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction

PR Newswire May 20, 2022

Emotional Intelligence Ventures and Mycotopia enter a Definitive Agreement on $382M merger transaction

GlobeNewswire May 19, 2022

Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments

GlobeNewswire May 9, 2022

Mycotopia Therapies Partners with Public Policy Specialist PsychedelicsEUROPE to Explore Opportunities in the European Market

GlobeNewswire May 2, 2022

Mycotopia Therapies Inc. To Enter $13 Billion Medicinal Mushroom Market With HAVN Life Sciences' Biopharmaceuticals And Ei.Ventures MANA Products

GlobeNewswire March 21, 2022

Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom Sector With HAVN Life Sciences Inc.

GlobeNewswire March 17, 2022

Ehave Issues Shareholder Letter and Provides Corporate Update

GlobeNewswire January 31, 2022

Mycotopia Therapies Announces Ei.Ventures Acquires 12x12 Estate in The Sandbox in Anticipation of PSLY.COM Launch Post-Merger with Mycotopia Therapies in Q1 2022

GlobeNewswire January 6, 2022

Ehave Plans Stock Distribution; Mycotopia Therapies Plans To Merge With Ei. Ventures

GlobeNewswire December 8, 2021

Mycotopia and Ei.Ventures sign LOI to Explore Merger and Formation of PSLY.COM, a $360 Million Transaction, And Will Apply To List Shares On NASDAQ

GlobeNewswire December 7, 2021

Mycotopia Therapies Announces Plan to Develop Psychedelic Sublingual Tablet to Help Treat Depression

GlobeNewswire November 17, 2021

Mycotopia Therapies Appoints Experienced Mental Health Professional Senator Dr. Saphire Longmore M.B.B.S., DM As Chief Medical Officer Of Caribbean Affairs

GlobeNewswire November 10, 2021

Mycotopia Therapies Issues CEO Letter to Stockholders, Reports on Significant Progress and Outlook for 2021

GlobeNewswire November 4, 2021

Mycotopia Therapies Signs Agreement With Havn Life Sciences For Purchase of Psilocybin SPP

GlobeNewswire August 25, 2021

Life Clips Closes Transaction to Acquire Cognitive Apps Software Solutions Inc.

GlobeNewswire April 6, 2021

Psychedelic Joint Venture Between Mycotopia Therapies and Natural MedTech Brings Research and Drug Development to Test Active Ingredient In Psychedelics

GlobeNewswire March 22, 2021

Mycotopia Therapies (20/20 Global) to Launch PsyBioMed, a Biosynthetic Compound, a Biotech Company for the Global Production of Psychedelics

GlobeNewswire February 8, 2021

20/20 Global Announces It Has Applied for a Name and Stock Symbol Change with FINRA

GlobeNewswire February 8, 2021

20/20 Global, Inc. PsyTech the World's Most Recognized Psychedelic Conference to Host Live Webinar on New Approaches to Ketamine-Assisted Treatment Wednesday, January 27th 2021 at 12:00 EST

GlobeNewswire January 26, 2021